Mast Cell Activation Syndrome (MCAS): Diagnosis, Treatment, Triggers, and the MCAS-POTS-EDS Connection
At a Glance
- What it is: Mast Cell Activation Syndrome – a condition where mast cells release chemical mediators (histamine, prostaglandins, cytokines) excessively and inappropriately, causing symptoms across multiple organ systems.
- Key symptoms: Flushing, hives, itching, GI distress, brain fog, fatigue, tachycardia, throat tightness, and – in severe cases – anaphylaxis.
- The triad: MCAS frequently coexists with POTS (dysautonomia) and EDS (hypermobility) – finding one should prompt screening for the other two.
- Diagnosis challenge: Tryptase is often normal. Requires 24-hour urine N-methylhistamine and prostaglandin D2 metabolites during a flare. Response to treatment is part of the diagnostic criteria.
- Treatment approach: Layered – H1+H2 antihistamines first, then mast cell stabilizers, then advanced options like LDN or omalizumab for refractory cases.
- Major trigger: Mold exposure is one of the most potent and under-recognized MCAS triggers.
If you’ve been told your symptoms “don’t make sense” – that you can’t possibly have hives, brain fog, nausea, a racing heart, and throat tightness all from the same condition – let me tell you that you can. And there’s a name for it. Mast Cell Activation Syndrome is one of the most under-recognized and misunderstood conditions in medicine, partly because it affects so many organ systems simultaneously that no single specialist sees the full picture.
The average MCAS patient sees 10+ doctors before getting diagnosed. Many are told it’s anxiety, or that their labs are “normal” so nothing is wrong. This guide is designed to change that – to give you (and your providers) a clear understanding of what MCAS is, how to get diagnosed, what treatments actually work, and how MCAS connects to other conditions you may already be dealing with.
What Are Mast Cells and What Goes Wrong in MCAS?
Mast cells are sentinel immune cells that live in connective tissue throughout your body – concentrated in the skin, gut lining, respiratory tract, and around blood vessels and nerves. They’re essentially the immune system’s first responders, packed with 500-1,000 granules containing over 200 different chemical mediators including histamine, prostaglandins, leukotrienes, cytokines, and tryptase.
When functioning normally, mast cells do critical work: defending against pathogens, coordinating wound healing, mediating allergic responses, and regulating blood vessel tone. The problem in MCAS isn’t that you have too many mast cells (that’s mastocytosis) – it’s that your normal-count mast cells are stuck in a hypervigilant state, degranulating (releasing their chemical contents) in response to stimuli that should be harmless.
The result is a cascade of chemical mediators flooding tissues throughout your body – causing inflammation, vasodilation, smooth muscle contraction, nerve irritation, and immune dysregulation that can mimic dozens of different conditions simultaneously.
Key Concept – Why MCAS Symptoms Seem Random: Because mast cells exist in virtually every tissue, their inappropriate activation can produce symptoms in any organ system – skin, gut, lungs, heart, brain, and beyond. This is why MCAS patients often present with what looks like a baffling collection of unrelated problems. They’re not unrelated – they all trace back to the same hyperactive mast cells releasing the same chemical mediators in different tissues.
MCAS Symptoms: The Multi-System Picture
Histamine & Skin
Flushing (face, chest, neck – often triggered by heat, stress, or food), hives/urticaria that appear spontaneously, intense itching without visible rash, dermographism (skin writing – lines appear when skin is scratched), angioedema (swelling of lips, eyes, hands, feet), and skin that reacts to pressure, friction, or temperature changes.
GI & Respiratory
Abdominal pain and cramping, nausea, diarrhea (can alternate with constipation), bloating, multiple and shifting food intolerances, acid reflux, wheezing, shortness of breath, throat tightness, nasal congestion, and chronic rhinitis. Respiratory symptoms can mimic asthma but respond poorly to standard asthma treatment.
Neurological & Systemic
Brain fog and cognitive difficulty, severe fatigue, headaches and migraines, anxiety and panic attacks (histamine activates the sympathetic nervous system), insomnia, tachycardia and blood pressure instability, diffuse pain, temperature dysregulation, and – in severe cases – anaphylaxis or anaphylactoid reactions requiring epinephrine.
The hallmark of MCAS is that symptoms are episodic and unpredictable. Patients describe good days and terrible days with no apparent rhyme or reason – until they learn to identify their personal triggers. Symptoms tend to wax and wane, and flares can last hours to weeks.
Common MCAS Triggers
One of the most frustrating aspects of MCAS is that triggers vary enormously between patients. What devastates one person may not affect another at all. That said, these are the most commonly reported categories:
- Foods: High-histamine foods (aged cheese, fermented foods, alcohol, cured meats, citrus, shellfish), leftover foods (histamine increases as food ages), and foods that trigger your individual mast cells. See our histamine intolerance guide for detailed food lists.
- Environmental: Heat and cold exposure, sun, changes in barometric pressure, fragrances and chemicals, cleaning products, and – critically – mold.
- Physical: Exercise (especially intense or sustained), vibration, pressure on skin, friction, and physical overexertion.
- Emotional: Stress (one of the most potent triggers), strong emotions, sleep deprivation, and sympathetic nervous system activation.
- Hormonal: Menstrual cycle (estrogen directly promotes mast cell degranulation – many patients flare premenstrually), perimenopause, and hormonal fluctuations.
- Medications: NSAIDs, opioids, muscle relaxants, certain antibiotics (vancomycin, fluoroquinolones), contrast dyes, and some anesthetic agents.
- Infections: Viral, bacterial, or parasitic – even resolved infections can leave mast cells primed for months afterward.
⚠ Safety Warning – Mold as an MCAS Trigger: Mold exposure is one of the most potent and under-recognized drivers of mast cell activation. Mycotoxins (toxic compounds produced by certain molds) directly activate mast cells and can push a borderline MCAS case into full-blown reactivity. If your MCAS started or worsened after moving to a new home, started a new job, or experienced water damage, mold evaluation is essential. See our mold illness/CIRS guide for testing and remediation information. Treating MCAS without addressing ongoing mold exposure is often futile.
Diagnosis: Why It’s So Difficult and How to Get It Right
Diagnosing MCAS is notoriously challenging because standard lab work is often normal between flares, symptoms overlap with dozens of other conditions, and many physicians still aren’t familiar with the diagnostic criteria. The current consensus (Afrin et al., 2021) requires all three of the following:
- Episodic symptoms consistent with mast cell mediator release affecting two or more organ systems
- Objective evidence of mast cell mediator elevation during a symptomatic episode
- Response to mast cell-directed therapy (antihistamines, mast cell stabilizers)
Diagnostic Testing
| Test | What It Measures | Key Details | Practical Notes |
|---|---|---|---|
| Serum tryptase (baseline + during flare) | Mast cell degranulation marker | 20% rise above baseline + 2 ng/mL, OR >11.5 ng/mL during episode | Draw within 1-4 hours of flare onset; often normal in MCAS (unlike mastocytosis) |
| 24-hour urine N-methylhistamine | Histamine metabolite | More reliable than serum histamine (histamine half-life is only minutes) | Collect during a symptomatic period; refrigerate sample |
| 24-hour urine prostaglandin D2 / 11β-PGF2α | Prostaglandin release marker | Specific for mast cell-derived prostaglandins | Must be refrigerated during entire collection; heat degrades the sample |
| Plasma chromogranin A | Neuroendocrine activation marker | Elevated in many MCAS patients | False positives from PPI use, kidney disease, neuroendocrine tumors |
| Serum histamine | Direct histamine level | Half-life of only minutes in blood | Very high false-negative rate; often not useful clinically |
Key Concept – Testing During Flares Is Critical: The single biggest reason MCAS labs come back “normal” is that they’re drawn when the patient is feeling relatively well. Mediator levels can be completely normal between flares. Ideally, labs should be drawn within 1-4 hours of a symptomatic episode. The 24-hour urine collections should be done during a period when symptoms are active. If your tryptase was normal on a routine blood draw and your doctor said “it’s not MCAS,” that doesn’t rule it out – it just means the test wasn’t timed correctly.
MCAS vs. Systemic Mastocytosis vs. Histamine Intolerance
These three conditions are frequently confused. Understanding the differences guides treatment and prognosis.
| Feature | MCAS | Systemic Mastocytosis | Histamine Intolerance |
|---|---|---|---|
| Core problem | Normal-count mast cells that overreact | Too many mast cells (clonal proliferation) | Impaired histamine breakdown (DAO deficiency) |
| Mast cell number | Normal | Abnormally increased | Normal |
| Baseline tryptase | Usually normal | Typically >20 ng/mL | Normal |
| KIT mutation | Usually absent | Often present (D816V) | Absent |
| Bone marrow biopsy | Normal | Abnormal mast cell aggregates | Normal |
| Prevalence | Estimated 17% (Afrin et al.) | ~1 in 10,000 | ~1% of population |
| Symptom scope | Multi-system, episodic | Multi-system, often progressive | Primarily GI, skin, headaches – diet-related |
| Treatment | Layered mast cell-directed therapy | Hematology-directed, may need cytoreduction | DAO enzymes, low-histamine diet |
Treatment: A Layered Approach
MCAS treatment follows a stepwise, additive approach – you build layers of support until symptoms are adequately controlled. Most patients need multiple interventions working together.
Tier 1: H1 + H2 Antihistamines (First-Line)
Evidence Grade: Established
The foundation of MCAS treatment. Most patients require both H1 and H2 receptor blockers simultaneously:
- H1 blockers: Cetirizine (Zyrtec), loratadine (Claritin), fexofenadine (Allegra), or hydroxyzine. Many MCAS patients need higher doses than standard allergy dosing – up to 2-4x the over-the-counter dose, under physician supervision.
- H2 blockers: Famotidine (Pepcid) is the preferred H2 blocker – 20-40mg twice daily. It blocks histamine receptors in the gut and has a mild mast cell-stabilizing effect. Don’t skip this – H2 blockade addresses a different set of histamine receptors than H1 and is essential for GI symptoms.
Start both antihistamines at standard doses and titrate up as needed. Response to antihistamines is actually part of the diagnostic criteria – if you improve significantly on H1+H2 blockers, that supports the MCAS diagnosis.
Tier 2: Mast Cell Stabilizers
Evidence Grade: Promising
If antihistamines alone aren’t sufficient (and for most MCAS patients, they won’t be), the next layer targets the mast cells themselves – preventing degranulation rather than just blocking what they release:
- Cromolyn sodium (Gastrocrom): Oral mast cell stabilizer that works locally in the gut. Often dramatically effective for GI symptoms – nausea, cramping, diarrhea, food reactions. Available by prescription. Must be taken 15-20 minutes before meals.
- Quercetin: Natural flavonoid with well-documented mast cell-stabilizing properties. 500-1,000mg twice daily, taken with vitamin C for enhanced absorption. Well-tolerated and available over the counter. This is often one of the first supplements MCAS patients notice benefit from.
- Ketotifen: Combined antihistamine + mast cell stabilizer. Not commercially available as oral in the US – must be compounded. Available at doses of 0.5-2mg twice daily. Particularly useful for patients who need both antihistamine and stabilizer effects.
- Vitamin C: Natural antihistamine and mast cell stabilizer at doses of 1,000-2,000mg daily. Supports DAO enzyme function for histamine metabolism.
- DAO enzyme supplements: Diamine oxidase taken before meals helps break down dietary histamine before it’s absorbed, reducing the histamine load on an already overwhelmed system.
Tier 3: LDN (Low-Dose Naltrexone)
Evidence Grade: Promising
Low-dose naltrexone at 1.5-4.5mg nightly is emerging as a valuable tool for MCAS. It modulates the immune system through opioid receptor interactions, reduces neuroinflammation, and may help restore immune tolerance. Many MCAS patients report significant improvement in brain fog, fatigue, pain, and overall reactivity. LDN is especially useful when MCAS coexists with autoimmune features, chronic pain, or POTS.
Tier 4: Advanced Options for Severe/Refractory MCAS
Evidence Grade: Promising
- Omalizumab (Xolair): Anti-IgE monoclonal antibody given by injection. Originally developed for severe asthma, it’s showing remarkable results in severe MCAS that hasn’t responded to other treatments. Monthly injections; typically requires prior authorization and specialist management.
- Montelukast (Singulair): Leukotriene receptor blocker. Targets the leukotriene arm of mast cell mediator release – useful for respiratory, skin, and GI symptoms that don’t respond to antihistamines alone. Important caveat: can cause neuropsychiatric side effects (depression, anxiety, suicidality) in some patients – monitor closely.
- Compounded combinations: Specialized pharmacies can create custom formulations combining cromolyn, ketotifen, and other agents tailored to the individual patient’s symptom profile.
Diet and Environmental Management
Medication alone is rarely sufficient. Environmental and dietary management is equally important:
- Low-histamine diet: Reducing dietary histamine significantly lowers the total mediator burden on your system. See our histamine intolerance guide for food lists and meal planning.
- Trigger diary: Track symptoms alongside foods, environments, activities, stress levels, and menstrual cycle. Patterns often emerge after 2-4 weeks of consistent tracking.
- Mold avoidance: If mold is a trigger (and it is for many MCAS patients), environmental remediation is essential. Air filtration (HEPA), mold inspection, and potentially moving out of a contaminated space. See our mold illness guide.
- Stress management: Stress is one of the most potent mast cell triggers. Vagus nerve exercises and nervous system regulation techniques can meaningfully reduce mast cell reactivity.
- Fragrance-free products: Switch to unscented personal care, laundry, and cleaning products.
⚠ Safety Warning – Anaphylaxis Risk: Severe MCAS can cause anaphylaxis or anaphylactoid reactions – sudden-onset throat swelling, difficulty breathing, severe drop in blood pressure, and loss of consciousness. If you have MCAS with a history of severe reactions, you should carry injectable epinephrine (EpiPen) at all times and have an anaphylaxis action plan developed with your provider. Don’t assume your reactions will always stay mild – MCAS can be unpredictable, and the reaction that is manageable one day can escalate the next.
The MCAS-POTS-EDS Triad
This connection is so important it deserves its own section. MCAS frequently coexists with POTS (Postural Orthostatic Tachycardia Syndrome) and EDS (Ehlers-Danlos Syndrome). The triad is so common that finding one condition should automatically prompt evaluation for the other two.
The proposed mechanism: EDS involves defective collagen and connective tissue – the tissue where mast cells reside. Abnormal connective tissue may create a dysfunctional environment that makes mast cells more prone to inappropriate activation (MCAS). The chemical mediators released by activated mast cells – particularly histamine and prostaglandins – directly affect blood vessel tone and autonomic nervous system function, contributing to the tachycardia, blood pressure instability, and orthostatic intolerance seen in POTS.
In practical terms: if you have hypermobility (EDS), a racing heart when you stand up (POTS), and mysterious multi-system symptoms (MCAS), you may have all three – and treating each one helps the others.
Key Concept – The Triad Connection: Hypermobile EDS (defective connective tissue) → unstable mast cell environment → MCAS (inappropriate mast cell activation) → histamine and prostaglandin release → blood vessel dysregulation → POTS (autonomic dysfunction). This is why treating MCAS with mast cell stabilizers often improves POTS symptoms, and why managing POTS with compression and salt loading reduces the triggers for mast cell flares.
Frequently Asked Questions
Is MCAS an autoimmune disease?
Not in the classic sense. MCAS is immune dysregulation – your mast cells are overreactive, but they’re not attacking your own tissues the way autoimmune antibodies do. However, MCAS can coexist with autoimmune conditions, and some researchers believe chronic mast cell activation may contribute to autoimmune processes by disrupting immune tolerance and promoting chronic inflammation.
Can MCAS be cured?
Currently, MCAS is managed rather than cured. The good news: many patients achieve very good symptom control with the right combination of medications, dietary changes, and trigger avoidance. Some patients experience periods of significant remission, especially after addressing underlying contributors like SIBO, mold exposure, chronic infections, or hormonal imbalances. The goal is to reduce the total burden on mast cells until they return to a less reactive baseline.
How is MCAS diagnosed if labs are normal?
Normal labs between flares don’t rule out MCAS. The diagnostic criteria specifically require mediator testing during a symptomatic episode. If your tryptase was normal on a routine blood draw, ask your provider to order 24-hour urine N-methylhistamine and prostaglandin D2 metabolites, collected during a symptomatic period. a documented clinical response to mast cell-directed therapy (H1+H2 antihistamines, cromolyn) fulfills the third diagnostic criterion even when labs are difficult to capture.
What is a mast cell flare?
A flare is an episode of increased mast cell activation with worsening symptoms – potentially affecting any combination of organ systems. Flares can last hours to weeks and may be triggered by an identifiable event (food, stress, heat, hormonal change) or occur seemingly spontaneously. Flare management: increase baseline medications (higher antihistamine doses), strict trigger avoidance, rest, hydration, and in severe cases, use of rescue medications including epinephrine.
What is the connection between MCAS and POTS?
Histamine and prostaglandins released by activated mast cells directly affect blood vessel tone – causing vasodilation that drops blood pressure and triggers compensatory tachycardia. This is why many POTS patients find that their heart rate and orthostatic symptoms worsen during MCAS flares and improve when mast cells are better controlled. Up to 50% of POTS patients may have underlying MCAS as a contributing factor.
Is MCAS genetic?
There appears to be a genetic predisposition. MCAS often runs in families, and researchers have identified potential variants in genes involved in mast cell function (including KIT and related pathways). The typical pattern: genetic predisposition + environmental trigger (infection, mold exposure, physical trauma, emotional stress, hormonal change) = clinical MCAS. This is why MCAS often emerges after a specific triggering event rather than being present from birth.
What should I eat with MCAS?
Start with a low-histamine diet: avoid aged cheeses, fermented foods, cured meats, alcohol, vinegar, leftover foods, and canned fish. Eat fresh foods prepared and consumed quickly. Many MCAS patients also react to high-oxalate foods, lectins, or specific individual triggers unrelated to histamine content. A systematic elimination and reintroduction approach – guided by a symptom diary – is the most effective way to identify your personal dietary triggers. See our histamine intolerance guide for thorough food lists.
How do I find a doctor who understands MCAS?
Look for allergist/immunologists, functional medicine physicians, or integrative medicine specialists who specifically mention MCAS in their practice focus. Key indicators of a knowledgeable provider: they’re familiar with the consensus diagnostic criteria, use a layered treatment approach (not just “take Zyrtec”), consider the MCAS-POTS-EDS connection, are experienced with mast cell stabilizers (cromolyn, ketotifen), and are willing to pursue testing during flares rather than dismissing normal baseline labs.
Related Topics
- MCAS Symptoms – Detailed organ-by-organ symptom breakdown and tracking tools
- POTS (Postural Orthostatic Tachycardia Syndrome) – Diagnosis, treatment, and the MCAS connection
- Ehlers-Danlos Syndrome – Hypermobility, diagnosis, and how EDS drives MCAS and POTS
- Histamine Intolerance – Diet strategies, DAO enzymes, and reducing histamine load
- Low-Dose Naltrexone (LDN) – Immune modulation for MCAS, chronic pain, and autoimmunity
- Brain Fog – Neuroinflammation, histamine, and cognitive dysfunction
- Mold Illness / CIRS – One of the most potent MCAS triggers and how to address it
- SIBO – Gut inflammation as a driver of mast cell activation
References
- Afrin LB, et al. Diagnosis of mast cell activation syndrome: a global “consensus-2.” Diagnosis. 2021;8(2):137-152.
- Molderings GJ, et al. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10.
- Theoharides TC, et al. Mast cells, brain inflammation and autism. Eur J Pharmacol. 2016;778:96-102.
- Seneviratne SL, et al. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C. 2017;175(1):226-236.
- Valent P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125-1133.
- Weinstock LB, et al. Mast cell activation syndrome and the link with EDS and POTS. Clin Rev Allergy Immunol. 2021;60(3):452-460.
- Afrin LB. Never Bet Against Occam: Mast Cell Activation Disease and the Modern Epidemics of Chronic Illness and Medical Complexity. Sisters Media, 2016.
